Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00278161 · FLOW

Participant flow

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma · Source last updated 2018-11-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support. Pegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide. Rituximab: 375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52. Cyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.
    id
    FG000
    title
    R-HiCy
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        11
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        81
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        70
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
16 participants were screen failures. IRB allowed 3 of those participants to be analyzed along with the 78 who were treated as part of the study. Because the 3 additional participants received the exact same protocol intervention, the total population for analysis purposes is 81.
Complete source fields
groups
  1. description
    Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support. Pegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide. Rituximab: 375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52. Cyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.
    id
    FG000
    title
    R-HiCy
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        11
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        81
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        70
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
16 participants were screen failures. IRB allowed 3 of those participants to be analyzed along with the 78 who were treated as part of the study. Because the 3 additional participants received the exact same protocol intervention, the total population for analysis purposes is 81.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice